Theravance Biopharma, Inc.
NASDAQ: TBPH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Rick E. Winningham
- Employees
- 90
- Headquarters
- South San, United States
- IPO year
- 2014
- Market cap
- $890.3M
- Website
- https://www.theravance.com
Loading TBPH…
Loading profile data…Frequently asked questions about TBPH
What does Theravance Biopharma, Inc. (TBPH) do?
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, W...
Where does TBPH trade?
Theravance Biopharma, Inc. (TBPH) trades on the NASDAQ.
What sector is TBPH in?
Theravance Biopharma, Inc. (TBPH) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Theravance Biopharma, Inc.?
Rick E. Winningham is the chief executive officer of Theravance Biopharma, Inc. (TBPH).
Where is Theravance Biopharma, Inc. headquartered?
Theravance Biopharma, Inc. is headquartered in United States.
Does TBPH pay a dividend?
Theravance Biopharma, Inc. (TBPH) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TBPH go public?
Theravance Biopharma, Inc. (TBPH) completed its initial public offering in 2014.